Terms: = Prostate cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Treatment
23 results:
1. GH Action in prostate cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract] [Full Text] [Related]
2. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
Shaw V; Srivastava S; Srivastava SK
Semin Cancer Biol; 2021 Jan; 68():75-83. PubMed ID: 31618686
[TBL] [Abstract] [Full Text] [Related]
3. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant prostate cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.
Udhane V; Maranto C; Hoang DT; Gu L; Erickson A; Devi S; Talati PG; Banerjee A; Iczkowski KA; Jacobsohn K; See WA; Mirtti T; Kilari D; Nevalainen MT
Mol Cancer Ther; 2020 Jan; 19(1):231-246. PubMed ID: 31548294
[TBL] [Abstract] [Full Text] [Related]
4. Role of Holmium laser enucleation of the prostate to increase cancer detection rate in patients with gray-zone PSA level.
Kim KH; Kim SW; Son HS; Kim DK; Jung DC; Kim HW; Kim JC; Hong SJ; Kim JH
Minerva Urol Nefrol; 2019 Feb; 71(1):72-78. PubMed ID: 30037211
[TBL] [Abstract] [Full Text] [Related]
5. Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma.
Elmaci I; Altinoz MA
Crit Rev Oncol Hematol; 2018 Aug; 128():96-109. PubMed ID: 29958636
[TBL] [Abstract] [Full Text] [Related]
6. stat5A/B Blockade Sensitizes prostate cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
7. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract] [Full Text] [Related]
8. Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.
Chen KE; Bustamante K; Nguyen V; Walker AM
Oncotarget; 2017 May; 8(22):36368-36382. PubMed ID: 28422740
[TBL] [Abstract] [Full Text] [Related]
9. Prolactin-induced prostate tumorigenesis.
Sackmann-Sala L; Goffin V
Adv Exp Med Biol; 2015; 846():221-42. PubMed ID: 25472541
[TBL] [Abstract] [Full Text] [Related]
10. Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through stat5 activation via glucocorticoid receptor pathway.
Song C; Kim Y; Min GE; Ahn H
Prostate; 2014 Sep; 74(12):1240-8. PubMed ID: 25043756
[TBL] [Abstract] [Full Text] [Related]
11. Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.
Joung YH; Na YM; Yoo YB; Darvin P; Sp N; Kang DY; Kim SY; Kim HS; Choi YH; Lee HK; Park KD; Cho BW; Kim HS; Park JH; Yang YM
Int J Oncol; 2014 Mar; 44(3):883-95. PubMed ID: 24402583
[TBL] [Abstract] [Full Text] [Related]
12. Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment.
Sustarsic EG; Junnila RK; Kopchick JJ
Biochem Biophys Res Commun; 2013 Nov; 441(1):144-50. PubMed ID: 24134847
[TBL] [Abstract] [Full Text] [Related]
13. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.
Iglesias-Gato D; Chuan YC; Wikström P; Augsten S; Jiang N; Niu Y; Seipel A; Danneman D; Vermeij M; Fernandez-Perez L; Jenster G; Egevad L; Norstedt G; Flores-Morales A
Carcinogenesis; 2014 Jan; 35(1):24-33. PubMed ID: 24031028
[TBL] [Abstract] [Full Text] [Related]
14. IGF-1R modulation of acute GH-induced stat5 signaling: role of protein tyrosine phosphatase activity.
Gan Y; Zhang Y; Buckels A; Paterson AJ; Jiang J; Clemens TL; Zhang ZY; Du K; Chang Y; Frank SJ
Mol Endocrinol; 2013 Nov; 27(11):1969-79. PubMed ID: 24030252
[TBL] [Abstract] [Full Text] [Related]
15. Transcription factor stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract] [Full Text] [Related]
16. N-terminal truncation of stat5a/b circumvents PIAS3-mediated transcriptional inhibition of stat5 in prostate cancer cells.
Dagvadorj A; Tan SH; Liao Z; Xie J; Nurmi M; Alanen K; Rui H; Mirtti T; Nevalainen MT
Int J Biochem Cell Biol; 2010 Dec; 42(12):2037-46. PubMed ID: 20854925
[TBL] [Abstract] [Full Text] [Related]
17. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract] [Full Text] [Related]
18. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.
Chang M; Kanwar N; Feng E; Siu A; Liu X; Ma D; Jongstra J
Mol Cancer Ther; 2010 Sep; 9(9):2478-87. PubMed ID: 20667852
[TBL] [Abstract] [Full Text] [Related]
19. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.
Singh RP; Raina K; Deep G; Chan D; Agarwal R
Clin Cancer Res; 2009 Jan; 15(2):613-21. PubMed ID: 19147767
[TBL] [Abstract] [Full Text] [Related]
20. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/stat5b pathway.
Amorino GP; Deeble PD; Parsons SJ
Oncogene; 2007 Feb; 26(5):745-56. PubMed ID: 16862179
[TBL] [Abstract] [Full Text] [Related]
[Next]
